TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8072258
Drug: Progressive tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive tapering of CsA after prolonged remission of more than one year
Study: 28355039
Drug: Elevated vacuum
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated vacuum suspension (EVS)
Study: 1979462
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of neuroleptics and antidepressants
Study: 1485367
Drug: Chronic dosing
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic dosing of ibuprofen
Study: 31714986
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid (180 mg)
Study: 21562484
Drug: Ketanserin 50
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 50 mg - Placebo
Study: 9642379
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium gluconate (3 g/day)
Study: 19804455
Drug: Cytarabine given
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine given for 5 days combined with cyclophosphamide for 3 days and topotecan by continuous infusion for 5 days (Arm C)
Study: 11986206
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (300 to 1000 mg per day)
Study: 11200306
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug treatment groups
Study: 10883741
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups
Study: 28017403
Drug: Immediate vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vaccination with rVSV-ZEBOV (2×10^7 plaque-forming units administered intramuscularly)
Study: 6859372
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum antisperm antibody titer below 512
Study: 21173411
Drug: Unblinded echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinded echinacea pills
Study: 21173411
Drug: Blinded echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded echinacea pills
Study: 21173411
Drug: Open-label echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label echinacea pills
Study: 31785463
Drug: Oral trofosfamide
Normalized name: trofosfamide
DrugBank: Trofosfamide (DB12902)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trofosfamide (arm B)
Study: 31337325
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation Therapy
Study: 24957950
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (Intanza)
Study: 21393260
Drug: Graded running
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded running programme with additional shockwave therapy (ESWT)
Study: 22132711
Drug: 4-mg intravitreal
Normalized name: ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-mg intravitreal injections of triamcinolone acetonide (IVTA); 21 patients in the IVTA group
Study: 3125788
Drug: Fleroxacin 100
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 100 mg intravenous infusion
Study: 1773780
Drug: CBZ 400
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ 400 mg
Study: 24092978
Drug: Rivastigmine 18
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine 18 mg patch without domperidone (RWOD)
Study: 28729021
Drug: Ceritinib 450
Normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ceritinib 450 mg with food
Study: 8034208
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (3000 cGy)
Study: 3914180
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 100 mg daily
Study: 23910233
Drug: One-third dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-third dose BCG
Study: 12087932
Drug: Gel subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel subgroup (EP)
Study: 1831533
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of OK‐432
Study: 8454328
Drug: CMR vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMR vaccine 240 micrograms
Study: 26304466
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg/d
Study: 21342412
Drug: Saxagliptin +
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin + Metformin
Study: 26431650
Drug: Human Urinary
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Urinary Kallikrein injection (0.15 PNA unit) plus 100 mL saline, intravenous infusion, once a day for 14 days
Study: 21829006
Drug: IT peribulbar
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT peribulbar injection
Study: 28560853
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (gefitinib combined with pemetrexed and carboplatin)
Study: 28984632
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg orally administered on the day before PCI and on the day of PCI
Study: 22853642
Drug: Unstructured physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unstructured physical activity (UPA) - 30 min supervised unstructured free playtime, twice daily
Study: 21275922
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) treatment during the active hormone phase (OC phase)
Study: 28844193
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with dabigatran (110 mg twice daily)
Study: 8528053
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose groups
Study: 11485375
Drug: L-NMMA alone
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA alone
Study: 21214718
Drug: 6-month intervention
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month intervention program (cycle ergometer training twice a day for 5 days a week and a hypocaloric diet)
Study: 3691273
Drug: Intravenous cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisapride
Study: 15971275
Drug: NicQb vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NicQb vaccine
Study: 25017924
Drug: Non-oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-oral hormone therapy (1.5 mg/day percutaneous 17β-estradiol gel or equivalent for nasal route for 3 months followed by 200 mg/day micronized progesterone by the vaginal route for 14 days during each menstrual period)
Study: 18504612
Drug: IV ibandronic
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ibandronic acid 6 mg infused over 15 min every 28 days
Study: 1699443
Drug: HS-HES solution
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-HES solution (72 g/l NaCl, 60 g/l HES, 2400 mosmol/l)
Study: 21829969
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanic acid (ACG)
Study: 9742976
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with sulphonylureas or insulin
Study: 18641546
Drug: Concentration-controlled MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration-controlled MMF therapy
Study: 20670958
Drug: Fixed-dose MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose MMF therapy
Study: 3418376
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy
Study: 24816198
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 50 mg/d
Study: 24816198
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 150 mg/d
Study: 24816198
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg/d
Study: 2486951
Drug: Fentiazac 100
Normalized name: fentiazac
DrugBank: Fentiazac (DB13217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentiazac 100 mg every 12 hrs for 5 days
Study: 29141679
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (10 IU in 1 mL given slowly over 1 min)
Study: 11065040
Drug: Once-weekly drug-in-adhesive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-weekly drug-in-adhesive (DIA) patches
Study: 29442239
Drug: MA 320
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 320 mg/day plus celecoxib 200 mg/day
Study: 21195592
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain wheat sourdough bread (162.5 g)
Study: 21195592
Drug: Refined white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined white bread (168.8 g)
Study: 3103414
Drug: Supramaintenance infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supramaintenance infusion (2.77 +/- 0.2 times fasting M, n = 14)
Study: 2288833
Drug: Nifedipine R
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine R 20 mg twice daily
Study: 1904749
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen (all doses)
Study: 9934939
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (400 mg of intramuscular testosterone cypionate biweekly for 8 weeks)
Study: 15545185
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1600 mg daily for 3 years
Study: 22704583
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1600 mg daily for 3 years (in women age 50 years or older)
Study: 10701032
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 100 micrograms/kg at the end of surgery (Group 2)
Study: 25293388
Drug: n-3 FA
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 FA deficient sunflower oil high oleic (7.5 ml b.i.d.)
Study: 17050586
Drug: Azimilide 125
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 125 mg/day
Study: 20372991
Drug: Azithromycin capsules
Normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin capsules (fasted state)
Study: 10443654
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch
Study: 21235696
Drug: Initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combination therapy with sitagliptin and pioglitazone
Study: 24261644
Drug: Intravenous haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous haloperidol 2 mg/q8h
Study: 3299566
Drug: Ambroxol 120
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 120 mg/day
Study: 21445604
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (COLD)
Study: 18375270
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at 5 mL/hr (placebo)
Study: 9800147
Drug: Lamotrigine 500
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine 500 mg
Study: 16870076
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a commercial NRL extract
Study: 11250761
Drug: Finasteride cream
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride cream (0.25%)
Study: 17625124
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a and ribavirin for 16 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Study: 17625124
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a and ribavirin for 24 weeks (with pretreatment serum HCV RNA level of 400,000 IU/ml or less)
Study: 11444452
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg plus bupivacaine 1.25 mg (Group F)
Study: 23131813
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (1.0 g sachets, 3 cups per day for 60 days)
Study: 21281873
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT)
Study: 17077230
Drug: Increased access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increased access to emergency contraceptive pills (two packages dispensed in advance with unlimited resupply at no charge)
Study: 27439408
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) therapy
Study: 21647578
Drug: Org 26576
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26576 (0.1-10 mg/kg, i.v.)
Study: 8873580
Drug: Hydrochlorothiazide (HCT2)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT2) 24 mg daily
Study: 26202594
Drug: Onartuzumab plus
Normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab plus placebo plus weekly paclitaxel (OP)
Study: 17297382
Drug: Cellulose sulfate
Normalized name: CELLULOSE SULFATE
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose sulfate (CS) gel
Study: 8619109
Drug: Pre-operative internal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative internal brachytherapy (two alternative doses)
Study: 30949906
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp)
Study: 2011924
Drug: Low-dose alpha-IFN
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alpha-IFN (1.5 MU/day with the same schedule and for the same period)
Study: 15198763
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (0.8 mg)
Study: 16260342
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (0.8 mg)
Study: 7791814
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclosporine (2.5 to 5 mg per kilogram of body weight per day) and methotrexate (at the maximal tolerated dose)
Study: 27356547
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (50 µg)
Study: 14586213
Drug: Bryostatin-1 120
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 120 mug/m(2) as a 72-h continuous infusion every 2 weeks (Regimen II)
Study: 7134228
Drug: Aluminium oxide
Normalized name: Aluminium oxide
DrugBank: Aluminum oxide (DB11342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium oxide adsorbate vaccines (54, 108, and 216 IU/dose)
Study: 30578542
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU weekly for 12 weeks)
Study: 26487300
Drug: Monthly survey
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly survey plus tailored risk reduction messages
Study: 7615781
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta 2 agonist with inhaled corticosteroids
Study: 14625122
Drug: Hormonal Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal Replacement Therapy (HRT)
Study: 22840829
Drug: 10-week exercise
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10-week exercise intervention program consisting of supervised weekly 60-minute sessions and unsupervised 30 minutes of aerobic exercises 4 times each week.
Study: 10337433
Drug: Olopatadine ophthalmic
Normalized name: olopatadine ophthalmic
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine ophthalmic solution (0.1%)
Study: 7586929
Drug: Felbamate 2400
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate 2400 mg/day
Study: 21175801
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of 0.1 mol/L hydrochloric acid
Study: 27993387
Drug: Simvastatin (SIMVA)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SIMVA) 20 mg/d
Study: 9750805
Drug: Transarterial brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial brachial plexus blockade with injection of 2/3 of the anaesthetic in back of and 1/3 in front of the artery (group TAP)
Study: 9750805
Drug: Transarterial brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial brachial plexus blockade with one single injection in back of the artery (group TP)
Study: 8229497
Drug: Chlorpromazine alone
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine alone (30 mg/m2 given intravenously)
Study: 10340913
Drug: Thalidomide administration
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide administration
Study: 12753271
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CC)
Study: 17947832
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS)
Study: 12621386
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride (0.07 mg/kg)